Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-05-31
2011-05-31
Moore, Susanna (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S280000
Reexamination Certificate
active
07951810
ABSTRACT:
This invention relates to compounds of formula (I-A)wherein Ring A and the variables X, Y, R3a, R3b, R3c, R3d, R4, R5, R5′, and m are defined herein. The compounds of formula (I-A) inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds of the invention are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
REFERENCES:
patent: 3622561 (1971-11-01), Robins et al.
patent: 5039689 (1991-08-01), Daluge
patent: 5726302 (1998-03-01), Ugarkar et al.
patent: 5763596 (1998-06-01), Boyer et al.
patent: 5767097 (1998-06-01), Tam
patent: 5824657 (1998-10-01), Hill et al.
patent: 5864033 (1999-01-01), Browne et al.
patent: 6210917 (2001-04-01), Carson et al.
patent: 6734283 (2004-05-01), Chau
patent: 0832091 (2004-01-01), None
patent: 0832092 (2004-11-01), None
patent: 2284811 (1995-06-01), None
patent: 2287464 (1995-09-01), None
patent: 62-108897 (1987-07-01), None
patent: 11-228422 (1999-08-01), None
patent: 11-228446 (1999-08-01), None
patent: WO 03/049739 (2003-06-01), None
patent: WO 2005/007621 (2005-01-01), None
patent: WO 2006/002284 (2006-01-01), None
Baker, David C., et al., “An evaluation of certain chain-extended analogues of 9-β-D-arabinofuranosyladenine for antiviral and cardiovascular activity,”Journal of Medicinal Chemistry, vol. 26, No. 10 (1983) pp. 1530-1534.
Bernier, Stephane, et al., “Glutamylsulfamoyladenosine and pyroglutamylsulfamoyladenosine are competitive inhibitors ofE. coliglutamyl-tRNA synthetase,”Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 20, No. 1 (Feb. 2005) pp. 61-67.
Bloch, A., et al., “Inhibition of protein synthesis by 5'-sulfamoyladenosine,”Biochemistry, vol. 10, No. 24 (1971) pp. 4394-4398.
Bookser, Brett C., et al., “Adenosine kinase inhibitors. 4. 6,8-disubstituted purine nucleoside derivatives. Synthesis, conformation, and enzyme inhibition,”Journal of Medicinal Chemistry, vol. 48, No. 9 (2005) pp. 3389-3399.
Boyer, Serge H., et al., “Adenosine kinase inhibitors. 5. Synthesis, enzyme inhibition, and analgesic activity of diaryl-etythro-furanosyltubercidin analogues,”Journal of Medicinal Chemistry, vol. 48, No. 20 (2005) pp. 6430-6441.
Brown, Pamela, et al., “Molecular recognition of tyrosinyl adenylate analogues by prokaryotic tyrosyl tRNA synthetases,”Bioorganic&Medicinal Chemistry, vol. 7 (1999) pp. 2473-2485.
Crimmins, Michael T., et al., “An efficient, general asymmetric synthesis of carbocyclic nucleosides: application of an asymmetric aldol/ring-closing metathesis strategy,”Journal of Organic Chemistry, vol. 65, No. 25 (2000) pp. 8499-8509.
Gough, Geoffrey R., “New inhibitors of platelet aggregation. 5'-phosphate, 5'-phosphorothioate, and 5'-O-sulfamoyl derivatives of 2-substituted adenosine analogues,”Journal of Medicinal Chemistry, vol. 21, No. 6 (1978) pp. 520-525.
Kristinsson, Haukur, et al., “A novel synthesis of sulfamoyl nucleosides,”Tetrahedron, vol. 50, No. 23 (1994) pp. 6825-6838.
Kristinsson, Haukur, et al., “Herbicidally active sulfamoyl nucleosides,”ACS Symposium Series 584, Synthesis and Chemistry of Agrochemicals IV, Chapter 19, Baker, Don R., et al., editors (1995) pp. 206-219.
Kuang, Rongze, et al., Enantioselective syntheses of carbocyclic ribavirin and its analogs: linear versus convergent approaches,Tetrahedron Letters, vol. 41 (2000) pp. 9575-9579.
Lee, Jeewoo, et al., “N-alkoxysulfamide, N-hydroxysulfamide, and sulfamate analogues of methionyl and isoleucyl adenylates as inhibitors of methionyl-tRNA and isoleucyl-tRNA synthetases,”Bioorganic&Medicinal Chemistry Letters, vol. 13 (2003) pp. 1087-1092.
Pan, Zhen-Qiang, et al., “Nedd8 on cullin: building an expressway to protein destruction,”Oncogene, vol. 23 (2004) pp. 1985-1987.
Peterson, Eileen M., et al., “Synthesis and biological evaluation of 5'-sulfamoylated purinyl carbocyclic nucleosides,”Journal of Medicinal Chemistry, vol. 35, No. 22 (1992) pp. 3991-4000.
Shuman, Dennis A., et al., “The synthesis of nucleoside sulfamates related to nucleocidin,”Journal of the American Chemical Society, vol. 92, No. 11 (Jun. 3, 1970) pp. 3434-3440.
Somu, Ravindranadh V., et al., “Rationally designed nucleoside antibiotics that inhibit siderophore biosynthesis ofMycobacterium tuberculosis,” Journal of Medicinal Chemistry, vol. 49, No. 1 (2006) pp. 31-34.
Ubukata, Makoto, et al., “Total synthesis of nucleoside antibiotic, ascamycin,”Tetrahedron Letters, vol. 27, No. 33 (1986) pp. 3907-3908.
Ubukata, Makoto, et al., “Synthesis and biological activity of aminoacyl analogs of ascamycin,”Agricultural and Biological Chemistry, vol. 52, No. 5 (1988) pp. 1117-1122.
Ugarkar, Bheemarao G., et al., “Adenosine kinase inhibitors. 3. Synthesis, SAR, and anti-inflammatory activity of a series of L-lyxofuranosyl nucleosides,”Journal of Medicinal Chemistry, vol. 46, No. 22 (2003) pp. 4750-4760.
Winum, Jean-Yves, et al., “Sulfamates and their therapeutic potential,”Medicinal Research Reviews, vol. 25, No. 2 (2005) pp. 186-228.
International Search Report dated Jul. 17, 2006 from PCT/US2006/004637 corresponding to U.S. Appl. No. 11/346,649.
Office Action dated Sep. 14, 2009 in pending U.S. Appl. No. 11/700,614.
Advisory Action dated Dec. 14, 2009 in pending U.S. Appl. No. 11/700,614.
Terminal Disclaimer and Supplemental Reply filed Feb. 11, 2010 in pending U.S. Appl. No. 11/700,614.
Amendment and Response under 37 CFR §1.116 filed Nov. 13, 2009 in pending U.S. Appl. No. 11/700,614.
Critchley Stephen
Gant Thomas G.
Langston Steven P.
Olhava Edward J.
Peluso Stephane
Millennium Pharmaceuticals Inc.
Moore Susanna
LandOfFree
Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of E1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2658060